RecruitingPhase 2NCT05039619
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Sponsor: Hoffmann-La Roche
Indianapolis, IN · +10 more sites